{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:03:25Z","timestamp":1784070205866,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.mcna.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T09:18:18Z","timestamp":1681982298000},"page":"781-792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hepatorenal Syndrome"],"prefix":"10.1016","volume":"107","author":[{"given":"Justin M.","family":"Belcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2023.03.009_bib1","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/j.1572-0241.2001.03958.x","article-title":"Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis","volume":"96","author":"Hampel","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mcna.2023.03.009_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.14218\/JCTH.2019.00060","article-title":"Incidence, mortality and predictors of acute kidney injury in patients with cirrhosis: a systematic review and meta-analysis","volume":"8","author":"Tariq","year":"2020","journal-title":"J\u00a0Clin Transl Hepatol"},{"issue":"5","key":"10.1016\/j.mcna.2023.03.009_bib3","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2020.04.043","article-title":"Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis - a US population-based study","volume":"73","author":"Desai","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.mcna.2023.03.009_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/jim-d-15-00181","article-title":"Hepatorenal syndrome in hospitalized patients with chronic liver disease: results from the Nationwide Inpatient Sample 2002-2012","volume":"64","author":"Pant","year":"2016","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.mcna.2023.03.009_bib5","first-page":"108139","article-title":"Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis: a prospective cohort study","author":"Allegretti","year":"2015","journal-title":"Int J Hepatol"},{"issue":"6","key":"10.1016\/j.mcna.2023.03.009_bib6","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/hep.22605","article-title":"Acute kidney injury in cirrhosis","volume":"48","author":"Garcia-Tsao","year":"2008","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.mcna.2023.03.009_bib7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2021.08.016","article-title":"Terlipressin and the treatment of hepatorenal syndrome: How the CONFIRM trial moves the story forward","volume":"79","author":"Belcher","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.mcna.2023.03.009_bib8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2019.07.002","article-title":"New in the pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document","volume":"71","author":"Angeli","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.mcna.2023.03.009_bib9","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJM196906192802501","article-title":"Transplantation of cadaveric kidneys from patients with hepatorenal syndrome- Evidence for the functional nature of renal failure in advanced liver disease","volume":"280","author":"Koppel","year":"1969","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mcna.2023.03.009_bib10","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.V4101735","article-title":"Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy","volume":"4","author":"Epstein","year":"1994","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.mcna.2023.03.009_bib11","doi-asserted-by":"crossref","first-page":"m2687","DOI":"10.1136\/bmj.m2687","article-title":"Hepatorenal syndrome: pathophysiology, diagnosis and management","volume":"370","author":"Simonetto","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.mcna.2023.03.009_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-018-0022-7","article-title":"Hepatorenal syndrome","volume":"4","author":"Gin\u00e8s","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.mcna.2023.03.009_bib13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.14309\/ajg.0000000000000462","article-title":"Impaired cardiac reserve on dobutamine stress echocardiography predicts the development of hepatorenal syndrome","volume":"115","author":"Koshy","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.mcna.2023.03.009_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41581-019-0218-4","article-title":"Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis","volume":"16","author":"Velez","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.mcna.2023.03.009_bib15","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/hep.21920","article-title":"Model for end- stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure","volume":"46","author":"Thabut","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2023.03.009_bib16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jhep.2020.11.048","article-title":"The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis","volume":"74","author":"Arroyo","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.mcna.2023.03.009_bib17","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.3390\/ijms19103104","article-title":"Danger-associated molecular patterns (DAMPs): molecular triggers for sterile inflammation in the liver","volume":"19","author":"Mihm","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.mcna.2023.03.009_bib18","first-page":"351","article-title":"Recent advances in the pathogenetic mechanisms of sepsis-associated acute kidney injury","volume":"31","author":"Fani","year":"2018","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.mcna.2023.03.009_bib19","series-title":"Hepatorenal syndrome","first-page":"495","article-title":"Presentation of diagnostic criteria of the hepatorenal syndrome","author":"Earley","year":"1979"},{"issue":"4","key":"10.1016\/j.mcna.2023.03.009_bib20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"64","author":"Angeli","year":"2015","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2023.03.009_bib21","first-page":"1","article-title":"Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.mcna.2023.03.009_bib22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/j.ajkd.2010.11.032","article-title":"Clinical applications of biomarkers for acute kidney injury","volume":"57","author":"Belcher","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.mcna.2023.03.009_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hepr.13847","article-title":"Novel biomarkers of acute kidney injury in chronic liver disease: where do we stand after a decade of research?","volume":"53","author":"Yewale","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.mcna.2023.03.009_bib24","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1007\/s10620-012-2180-x","article-title":"Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis","volume":"57","author":"Verna","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.mcna.2023.03.009_bib25","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.26980","article-title":"Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury","volume":"60","author":"Belcher","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.mcna.2023.03.009_bib26","doi-asserted-by":"crossref","first-page":"e00359","DOI":"10.14309\/ctg.0000000000000359","article-title":"Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: A prospective study","volume":"12","author":"Allegretti","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"10.1016\/j.mcna.2023.03.009_bib27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.30592","article-title":"Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: A prospective study","volume":"70","author":"Huelin","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.mcna.2023.03.009_bib28","doi-asserted-by":"crossref","first-page":"e0128145","DOI":"10.1371\/journal.pone.0128145","article-title":"Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis","volume":"10","author":"Ariza","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.mcna.2023.03.009_bib29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jhep.2012.03.015","article-title":"Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis","volume":"57","author":"Fagundes","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.mcna.2023.03.009_bib30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.5604\/01.3001.0012.0931","article-title":"Urinary neutrophil gelatinase-associated lipocalin in cirrhotic patients with acute kidney injury","volume":"17","author":"Hamdy","year":"2018","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.mcna.2023.03.009_bib31","article-title":"Diagnostic and prognostic performance of urinary neutrophil gelatinase-associated lipocalin in patients with cirrhosis and acute kidney injury","author":"Gambino","year":"2022","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.mcna.2023.03.009_bib32","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1111\/hepr.12917","article-title":"Serum adrenomedullin and urinary thromboxane B2 help early categorizing of acute kidney injury in decompensated cirrhotic patients: A prospective cohort study","volume":"48","author":"Liu","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.mcna.2023.03.009_bib33","doi-asserted-by":"crossref","first-page":"376795","DOI":"10.1155\/2014\/376795","article-title":"Urinary biomarkers of acute kidney injury in patients with cirrhosis","volume":"2014","author":"Qasem","year":"2014","journal-title":"ISRN Nephrol"},{"key":"10.1016\/j.mcna.2023.03.009_bib34","doi-asserted-by":"crossref","first-page":"597","DOI":"10.7326\/0003-4819-96-5-597","article-title":"Nonoligouric acute renal failure associated with a low fractional excretion of sodium","volume":"96","author":"Diamond","year":"1982","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.mcna.2023.03.009_bib35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jceh.2021.09.019","article-title":"Fractional excretion of sodium and urea in differentiating acute kidney injury phenotypes in decompensated cirrhosis","volume":"12","author":"Gowda","year":"2022","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"2","key":"10.1016\/j.mcna.2023.03.009_bib36","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/nep.13226","article-title":"Biomarkers for acute kidney injury in decompensated cirrhosis: a prospective study","volume":"24","author":"Jaques","year":"2019","journal-title":"Nephrology"},{"issue":"1","key":"10.1016\/j.mcna.2023.03.009_bib37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hep.29772","article-title":"Fractional excretion of urea: a simple tool for the differential diagnosis of acute kidney injury in cirrhosis","volume":"68","author":"Patidar","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2023.03.009_bib38","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s10620-006-9312-0","article-title":"Octreotide\/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome","volume":"52","author":"Esrailian","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.mcna.2023.03.009_bib39","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/MCG.0b013e318188947c","article-title":"Combination treatment with octreotide, midodrine, and albumin improves survival in patients with Type 1 and Type 2 hepatorenal syndrome","volume":"43","author":"Skagen","year":"2009","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.mcna.2023.03.009_bib40","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2023.03.009_bib41","doi-asserted-by":"crossref","first-page":"675948","DOI":"10.3389\/fphar.2021.675948","article-title":"Norepinephrine is more effective than midodrine\/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled trial","volume":"12","author":"Mahmoud","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.mcna.2023.03.009_bib42","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.mcna.2023.03.009_bib43","first-page":"1","article-title":"In\u00a0vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2","volume":"10","author":"Jamil","year":"2017","journal-title":"J\u00a0Exp Pharmacol"},{"issue":"Pt A","key":"10.1016\/j.mcna.2023.03.009_bib44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.phrs.2016.08.027","article-title":"Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile","volume":"113","author":"Colson","year":"2016","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.mcna.2023.03.009_bib45","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A\u00a0randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mcna.2023.03.009_bib46","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.mcna.2023.03.009_bib47","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome","volume":"384","author":"Wong","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2023.03.009_bib48","first-page":"13","article-title":"Norepinephrine versus terlipressin in patients with type 1 hepatorenal syndrome refractory to treatment with octreotide, midodrine, and albumin: a prospective randomized comparative study","volume":"7","author":"Badawy","year":"2013","journal-title":"Egypt J Cardiothorac Anesth"},{"issue":"3","key":"10.1016\/j.mcna.2023.03.009_bib49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MEG.0000000000000537","article-title":"Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation","volume":"28","author":"Mattos","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.mcna.2023.03.009_bib50","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.30208","article-title":"Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure","volume":"71","author":"Arora","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.mcna.2023.03.009_bib51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.dld.2018.01.123","article-title":"Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome- A systematic review and meta-analysis","volume":"50","author":"Song","year":"2018","journal-title":"Dig Liver Dis"},{"issue":"11","key":"10.1016\/j.mcna.2023.03.009_bib52","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/lt.22395","article-title":"Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1","volume":"17","author":"Boyer","year":"2011","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.mcna.2023.03.009_bib53","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2215\/CJN.09600912","article-title":"Short-term pretransplant renal replacement therapy and renal nonrecovery after liver transplantation","volume":"8","author":"Sharma","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.mcna.2023.03.009_bib54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1523-1755.2005.00408.x","article-title":"Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy","volume":"68","author":"Wong","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2023.03.009_bib55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2215\/CJN.03610417","article-title":"Prognosis of patients with cirrhosis and AKI who initiate RRT","volume":"13","author":"Allegretti","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.mcna.2023.03.009_bib56","doi-asserted-by":"crossref","first-page":"819","DOI":"10.34067\/KID.0005182020","article-title":"Renal recovery and mortality risk among patients with hepatorenal syndrome receiving chronic maintenance dialysis","volume":"2","author":"McAllister","year":"2021","journal-title":"Kidney360"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712523000421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712523000421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:47:07Z","timestamp":1758419227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712523000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0025712523000421"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2023.03.009","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatorenal Syndrome","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}